What We're Reading: Page 179
Industry reads hand-picked by our editors
Oct 16, 2020
-
The Wall Street Journal
NIH to Study Three Drugs in Treatment of Covid-19 Patients
-
FierceBiotech
Galapagos' osteoarthritis drug flunks Phase 2, dashing hopes of $250M Gilead deal
-
S&P Global
Trump ally Chris Christie among the few to get Lilly COVID-19 antibody drug
-
The New York Times
U.S. Investigates Vaxart's Claims Related to Covid-19 Vaccine
Oct 15, 2020
-
Bloomberg
FDA Chief Defends Vaccine-Trial Halts as Vital to Safety System
-
Endpoints News
Patient death in pivotal gene therapy trial rattles Sarepta partner already facing clinical hold
-
Future Human
Fresh Off Her Nobel Prize Win, Jennifer Doudna Predicts What’s Next for CRISPR
-
LifeSciVC
It’s Raining Biotech SPACs!
Oct 14, 2020
-
Reuters
FDA faults quality control at Lilly plant making Trump-touted COVID drug
-
STAT
Selling stock at a clip, top Moderna doctor gets $1 million richer each week
-
FierceBiotech
Cyclerion fails sickle cell test, prompting pivot to CNS disease
-
Politico
FDA pushes back on Trump administration attempt to rebrand 'emergency authorization'
Oct 13, 2020
-
The New York Times
The Race for a Super-Antibody Against the Coronavirus
-
STAT
How would doctors and insurers navigate demand for a new, narrow Alzheimer's drug?
-
In the Pipeline
Another Vaccine Trial Halt
Oct 12, 2020
-
Politico
Pfizer trying to defuse critics amid push for vaccine before Election Day
-
Wired
Trump's 'Miracle Cure' for Covid Is a Logistical Nightmare
-
Barron's
Pfizer Suit Could Be an 'Earthquake' for Drug Pricing
-
FierceBiotech
You've met Moderna, BioNTech and Curevac. Now meet Kernal Bio, the startup working on mRNA 2.0
Previous
